News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
AbiVax drug shows best efficacy but cancer cases tank stock 30%
AbiVax's obefazimod delivered efficacy results analysts called best-in-disease for ulcerative colitis, but cancer cases reported in treatment recipients wiped out gains and sent shares down more than 30%.
Fulcrum's sickle cell drug stalled by FDA, company explores sale
Fulcrum Therapeutics faces an FDA setback on its sickle cell medicine and is exploring a potential sale. The stumble mirrors recent failures from Pfizer, Novartis, and Intellia in the same disease area.
Eli Lilly demands 340B hospitals prove drug discount compliance by Monday
Eli Lilly set a data-sharing deadline for select hospitals to demonstrate they're not exploiting federal drug discounts. Some facilities are pushing back, asking the government to intervene.
Celcuity breast cancer drug misses efficacy bar despite investor hype
Gedatolisib failed to meet primary endpoints in a pivotal PIK3CA-mutated breast cancer trial, deflating investor expectations despite investigator claims of potential standard-of-care status.
Lilly, Ascidian Strike $1.9B RNA Editing Deal for Kidney Disease
Eli Lilly partners with Ascidian Therapeutics in a deal worth up to $1.9 billion to develop RNA exon-editing treatments for genetic kidney diseases. What this means for the RNA therapeutics pipeline.
Healthcare consent rules lag other industries by years
Healthcare systems lack the consent flexibility that finance, retail, and tech have adopted. Two major conferences will tackle the gap between AI ambition and evidence-based deployment.
HIMSS Conferences Bring AI Healthcare From Theory to Clinical Practice
Two HIMSS events in 2026 will convene clinicians, technologists, and executives to bridge the gap between AI ambition and real-world deployment in healthcare systems across Asia-Pacific and Boston.
Elation Health buys Aster to add AI voice agent for clinic front-office work
Elation Health acquired Aster, a women's health EHR startup founded in 2023, to integrate its Atlas voice AI agent for automating patient-facing tasks. The deal follows Elation's earlier embedding of Anthropic's Claude into its clinical tools.
ResMed buys Noctrix for $340M to own restless legs syndrome treatment
ResMed completed its $340 million acquisition of Noctrix Medical, gaining control of a noninvasive therapy for restless legs syndrome. The deal expands ResMed's portfolio beyond sleep and respiratory care into neurological disorders.
Grail's cancer test shows promise, but ASCO wants more proof
Grail presented positive signals from its Galleri multi-cancer early detection study at ASCO, though the medical society says independent evidence is needed before adding it to screening guidelines.
Eli Lilly sets Monday deadline for 340B hospital data or loses drug discounts
Eli Lilly is demanding hospitals prove they're not double-dipping on drug discounts under the 340B program. Hospitals refusing to share data have until Monday to comply or face consequences.
Clinicians fear AI will erode their decision-making skills
Three-quarters of clinicians surveyed by Wolters Kluwer cite deskilling as the greatest risk of AI adoption in healthcare. What hospitals are doing about it.